Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma

NCT06705725 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: CBG002 CAR-T Cell Suspension

Sponsor

Carbiogene Therapeutics Co. Ltd.